David A. Siegel Theravance Biopharma, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 29,100 shares of TBPH stock, worth $408,564. This represents 0.0% of its overall portfolio holdings.
Number of Shares
29,100
Previous 24,700
17.81%
Holding current value
$408,564
Previous $220,000
45.45%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding TBPH
# of Institutions
138Shares Held
48.5MCall Options Held
0Put Options Held
11.6K-
Madison Avenue Partners, LP New York, NY9.51MShares$134 Million11.23% of portfolio
-
Weiss Asset Management LP Boston, MA7.46MShares$105 Million1.24% of portfolio
-
Newtyn Management, LLC New York, NY4.95MShares$69.5 Million10.56% of portfolio
-
Black Rock Inc. New York, NY3.78MShares$53.1 Million0.0% of portfolio
-
Irenic Capital Management LP New York, NY2.76MShares$38.8 Million4.49% of portfolio
About Theravance Biopharma, Inc.
- Ticker TBPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,782,400
- Market Cap $938M
- Description
- Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...